Roivant Sciences Ltd. (ROIV)
NASDAQ: ROIV · Real-Time Price · USD
21.12
-0.53 (-2.45%)
Feb 5, 2026, 3:41 PM EST - Market open
Roivant Sciences Revenue
Roivant Sciences had revenue of $1.57M in the quarter ending September 30, 2025, a decrease of -64.89%. This brings the company's revenue in the last twelve months to $20.33M, down -45.13% year-over-year. In the fiscal year ending March 31, 2025, Roivant Sciences had annual revenue of $29.05M, down -11.19%.
Revenue (ttm)
$20.33M
Revenue Growth
-45.13%
P/S Ratio
731.28
Revenue / Employee
$27,105
Employees
750
Market Cap
14.69B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 29.05M | -3.66M | -11.19% |
| Mar 31, 2024 | 32.71M | 1.18M | 3.75% |
| Mar 31, 2023 | 31.53M | -23.76M | -42.97% |
| Mar 31, 2022 | 55.29M | 31.49M | 132.34% |
| Mar 31, 2021 | 23.80M | -43.89M | -64.85% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Incyte | 4.81B |
| Genmab | 3.85B |
| BioMarin Pharmaceutical | 3.09B |
| Exelixis | 2.29B |
| Moderna | 2.23B |
| Ionis Pharmaceuticals | 966.96M |
| Ascendis Pharma | 758.59M |
| BridgeBio Pharma | 353.78M |
ROIV News
- 12 days ago - Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026 - GlobeNewsWire
- 23 days ago - Roivant Sciences Ltd. (ROIV) Presents at 44th Annual J.P. - Seeking Alpha
- 4 weeks ago - Roivant Sciences Ltd. (ROIV) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Goldman Sachs Mid Cap Growth Fund Q3 2025 Investment Update - Seeking Alpha
- 7 weeks ago - Roivant Sciences Ltd. (ROIV) Analyst/Investor Day Transcript - Seeking Alpha
- 2 months ago - Roivant Highlights Continued Pipeline Progress and Outlook for Company's Next Phase of Growth at 2025 Investor Day - GlobeNewsWire
- 2 months ago - Roivant Sciences Ltd. (ROIV) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 3 months ago - Roivant Sciences: Brepocitinib And Roadmap Still Underpriced - Seeking Alpha